CRISPR Therapeutics prices $550M convertible notes due 2031 at 1.125% coupon

CRISPR Therapeutics AG

Aggregate principal amount upsized from $350M to $550M; net proceeds estimated at ~$536.3M.
Notes mature March 1, 2031; effective coupon 1.125% (1.7308% after Swiss withholding adjustment).
Initial conversion price ~$76.56 per share, a 45% premium over $52.80 closing price on March 10, 2026.
Holders may convert at any time prior to maturity; company may redeem after March 6, 2029 under certain conditions.
Proceeds for general corporate purposes; closing expected March 16, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.